![]() These cells maintain a person’s blood cells, replacing older or damaged cells with newer ones. If the chemotherapy is followed by an infusion of stem cells, these new stem cells can replace the cells in the bone marrow that were destroyed during the chemotherapy treatment.Ī stem cell is an immature cell in the bone marrow that can develop into mature blood cells. Potentially, the results of trials may provide sufficient evidence of clinical utility that a future NCD on this topic will provide coverage for such testing for all Medicare beneficiaries.The ability to transplant stem cells allows physicians to use higher doses of chemotherapy to treat the cancer than the body would normally tolerate, increasing the probability of killing cancer cells. Prospectively, in Medicare beneficiaries with MDS who receive HSCT, what treatment facility characteristics predict meaningful clinical improvement in the following outcomes:.Prospectively, in Medicare beneficiaries with MDS who receive HSCT, how do International Prognostic Scoring System (IPSS) score, patient age, cytopenias and comorbidities predict the following outcomes:.Prospectively, compared to Medicare beneficiaries with MDS who do not receive HSCT, do Medicare beneficiaries with MDS who receive HSCT have improved outcomes as indicated by:. ![]() The elements in this dataset, comprised of two mandatory forms plus one additional form, encompass the information we require for a study under CED.Ī prospective clinical study seeking Medicare payment for treating a beneficiary with allogeneic HSCT for MDS pursuant to CED must meet one or more aspects of the following questions: In accordance with the Stem Cell Therapeutic and Research Act of 2005 (US Public Law 109-129) a standard dataset is collected for all allogeneic transplant patients in the United States by the Center for International Blood and Marrow Transplant Research. ![]() The NCD specifies that allo HSCT for the treatment of MDS is covered only when provided to Medicare beneficiaries enrolled in an approved clinical studyĪllo HSCT is a procedure in which a portion of a healthy donor's stem cell or bone marrow is obtained and prepared for intravenous infusion. The NCD for Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) for the treatment of Myelodysplastic Syndromes (MDS), released by CMS in August 2010, concluded that, absent convincing evidence that allo HSCT improves patient health outcomes, additional research from clinical trials would be appropriate under the Coverage with Evidence Development aspect of CMS’ coverage authority. Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD).Transcatheter Edge-to-Edge Repair (TEER).Pharmacogenomic Testing for Warfarin Response.Percutaneous Left Atrial Appendage Closure (LAAC).Percutaneous Image-guided Lumbar Decompression for Lumbar Spinal Stenosis.Off-label use of Colorectal Cancer Drugs.FDG PET and Other Neuroimaging Devices for Dementia.Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome Following Lung Transplant. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |